Tuesday March 5 Oral Sessions Session 35 CROI <strong>2013</strong> e Tuesday, 4-6 pm; Ballroom 1-2 Session 35–Symposium When Worlds Collide —Adolescents and HIV, a symposium in memory of Edward Handelsman Conveners: Sabrina Bakeera-Kitaka, Makerere Univ, Kampala, Uganda Bill Kapogiannis, Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US 115 Ethical Issues in Adolescent HIV Prevention Research Sean Philpott Ctr for Bioethics and Clinical Leadership, Union Grad Coll, Schenectady, NY, US 116 What’s Fueling the HIV Epidemic in Gay/ Bisexual Male Adolescents and other Young MSM? Gary Harper Univ of Michigan Sch of Publ Hlth, Ann Arbor, US 117 Preventing New HIV Infections among Young African Women—Why Is It so Difficult? Sinead Delany-Moretlwe Univ of the Witwatersrand, Johannesburg, South Africa 118 Behavioral Challenges in Perinatally Infected Youth Claude Ann Mellins New York State Psychiatric Inst and Columbia Univ, New York, US Objectives: This session is designed for clinicians and scientists interested in challenging issues pertaining to adolescents and young adults living with HIV. It is assumed that participants are familiar with basic epidemiology of HIV in adolescents in high- and low-resource countries, and behavioral and sociologic issues observed in youth with adult risk behaviors and perinatally acquired HIV. At the completion of the session, participants will be knowledgeable about ethical considerations surrounding youth participation in vaccine and pre- and postexposure prophylaxis trials, foundations and accelerators of the epidemic in young MSM, impediments and successes in prevention strategies in young women in Africa, and mental health outcomes in youth who acquired HIV in infancy. 16 � 20th Conference on Retroviruses and Opportunistic Infections e Tuesday, 4-6 pm; Hall B1 Session 36–Symposium Opportunities and Threats to ART Success Conveners: Melanie Thompson, AIDS Res Consortium, Atlanta, GA, US Francois Venter, Wits Reproductive Hlth and HIV Res Inst, Johannesburg, South Africa 119 Political and Economic Threats to Sustainable ARV Treatment Jennifer Kates Kaiser Family Fndn, Washington, DC, US 120 ART and Inflammation: Implications for the Approach to Care in <strong>2013</strong> Sharon Lewin Alfred Hosp, Monash Univ and Burnet Inst, Melbourne, Australia 121 ARV Drug Resistance: Global Challenges Raph Hamers Academic Med Ctr of the Univ of Amsterdam;; Amsterdam Inst for Global Hlth and Devt;; PharmAccess Fndn, Amsterdam, The Netherlands 122 New HIV Drugs and Formulations: Effect on Therapeutic Paradigms Roy Gulick Weill Cornell Med Coll, New York, NY, US Objectives: This session is directed to clinicians and scientists interested in ART including threats to current progress, relationship to the chronic inflammatory state, and the promise of new agents and formulations. It is assumed that participants are familiar with the essentials of HIV pathogenesis and ARV therapeutics. At the completion of the session, participants will recognize the political and economic threats to sustaining the progress made in the era of potent ART, understand the role that artGG might play in the chronic immune activation state seen in HIV + persons with controlled viremia, appreciate the current stateof-the-art of ARV drug resistance, and gain knowledge of new ARV drugs and formulations and the implications for changing paradigms of therapy.
CROI <strong>2013</strong> Session 40 i Wednesday, 8:30-9 am; Hall B1 Session 37–Plenary Incorporating New Drugs into Regimens that Will Change the TB Treatment Paradigm: The Magic Mountain Meets Table Mountain 123 Andreas Diacon Stellenbosch Univ, Tygerberg, Cape Town, South Africa Objectives: This session is directed to clinicians and scientists interested in TB and anti-TB drugs. It is assumed that participants are familiar with the basics of clinical TB and current principles of TB treatment. At the completion of the session, participants will be informed about novel anti-TB drugs and regimens, the methods used to explore them, and how they might best be deployed to transform treatment of drug-susceptible and drug-resistant TB. j Wednesday, 9-9:30 am; Hall B1 Session 38–Plenary Treatment with Gene-modified Hematopoietic Stem Cells May Definitively Abolish HIV-1 Infection 124 Marina Cavazzana-Calvo U768 INSERM;; AP-HP, Hosp Univ Necker-Enfants Malades;; Univ Paris Descartes, Sorbonne Paris Cite, IMAGINE Inst;; CIC Biotherapie GHU Ouest, INSERM-APHP, Paris, France Objectives: This session is directed to clinicians and scientists interested in new genetic approaches for HIV-1 infections able to eliminate the need for indefinite treatment of infected patients. It is assumed participants are familiar with the human hematopoietic stem cell system as well as with the biological tools able to introduce de novo gene functions into these cells or alternatively to disrupt cellular genes to confer to the hematopoietic compartment a stable resistance to HIV. At the completion of the session, participants will be knowledgeable about the first clinical results obtained in this fastmoving field. k Wednesday, 10-11:45 am; B402 Session 39–Oral Abstracts New Discoveries in Vaccines and Gene Therapy Moderators: Richard Koup, Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US Alexandra Trkola, Univ of Zurich, Switzerland 10:00 125 Dendritic Cells Transduced with Vpx-packaged LV Vector Encoding CD40L Enhance Cytotoxic T Cell Responses and Disrupt HIV-1 Latency Thomas Norton*, E Miller, N Bhardwaj, and N Landau New York Univ Sch of Med, NY, US 10:15 126 Central Memory T Cell Is the Critical Component for Sustained CD4 Reconstitution in HIV Subjects Receiving ZFN CCR5 Modified CD4 T Cells (SB-728-T) J Zeidan1 , G Lee2 , J Lalezari3 , R Mitsuyasu4 , S Wang2 , M Giedlin2 , G Nichol2 , W Tang2 , ������������������� * 1 , and D Ando2 1Vector and Gene Therapy Inst of Florida, Port St Lucie, US;; 2 3 Sangamo BioSci, Richmond, CA, US;; Quest Clin Res, San Francisco, CA, US;; and 4Univ of California, Los Angeles, US 10:30 127 Protection of Stem Cells Results in Enhanced Virus-specific Immunity with Recovery of Unprotected CD4 + T Cells in a Primate AIDS Model Patrick Younan* 1 , P Polacino 2,3 , J Kowalski 1 , C Peterson 1 , N Maurice 1 , N Williams 1 , G Trobridge 1 , D Von Laer 4 , S-L Hu 2,3 , and H-P Kiem 1,2 1 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US;; 2 Univ of Washington, Seattle, US;; 3 Washington Natl Primate Res Ctr, Seattle, US;; and 4 Innsbruck Med Univ, Austria 10:45 128 Levels of CD4 + CCR5 + Target T Cells in Rectal Mucosa Predict Risk of SIV Acquisition and Replication in Rhesus Macaques Vaccinated with SIV Gag/Tat Vectors Diane Carnathan* 1 , K Sheehan 2 , J Yu 1 , D Weiner 2 , H Ertl 3 , and G Silvestri 1 1 Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US;; 2 Univ of Pennsylvania, Philadelphia, US;; and 3 The Wistar Inst, Philadelphia, PA, US 11:00 129 T Cells Edited to Express CCR5 or CXCR4 Fused to the C34 Peptide from gp41 Heptad Repeat-2 Exhibit Robust Protection from Diverse HIV-1 Isolates George Leslie* 1 , J Wang 2 , B Haggarty 1 , A Jordan 1 , J Romano 1 , K Hua 2 , M Holmes 2 , and J Hoxie 1 1 Univ of Pennsylvania, Philadelphia, US and 2 Sangamo BioSci Inc, Richmond, CA, US 11:15 130 Poor Neutralizing Antibody Response Is Associated with Subsequent HIV-1 Superinfection Gabriel Wagner* 1 , L Hepler 1 , G Caballero 2 , P Phung 3 , S Little 1 , S Kosakovsky Pond 1 , D Richman 1,2 , and D Smith 1,2 1 Univ of California, San Diego, La Jolla, US;; 2 VA Hlthcare System, San Diego, CA, US;; and 3 Monogram Biosci Inc, South San Francisco, CA, US 11:30 131LB Antibody-induced Perturbation of HIV-1 Env Structure Is a Quantifiable Parameter that Modulates the Inhibitory Potency of Antibodies Hillel Haim* 1,2 , I Salas 1 , and J Sodroski 1,3,4 1 DanaFarber Cancer Inst, Harvard Med Sch, Boston, MA, US;; 2 Carver Coll of Med, Univ of Iowa, Iowa City, US;; 3 Harvard Sch of Publ Hlth, Boston, MA, US;; and 4 Ragon Inst of MGH, MIT and Harvard, Boston, MA, US k Wednesday, 10 am-12 n; B406 Session 40–Oral Abstracts Virology: From the Outside In Moderators: Anna Aldovini, Children’s Hosp Boston, Harvard Univ, MA, US (invited) James Hoxie, Univ of Pennsylvania, Philadelphia, US 10:00 132 Transmitted/Founder HIV-1 Virions Exhibit High Env Content, Efficient Dendritic Cell Binding, Enhanced Infectivity, and Resistance to Alpha Interferon N Parrish 1 , E Giorgi 2 , C Wilen 1 , S Iyer 1 , J Kappes 3 , F Gao 4 , B Haynes 4 , B Korber 2 , G Shaw 1 , and Beatrice Hahn* 1 1 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; 2 Los Alamos Natl Lab, NM, US;; 3 Univ of Alabama at Birmingham, US;; and 4 Duke Univ Sch of Med, Durham, NC, US 10:15 133 Proteolytic Processing of the HIV Envelope Glycoprotein Precursor Decreases Conformational Flexibility Hillel Haim* 1,2 , I Salas 1 , and J Sodroski 1,3,4 1 DanaFarber Cancer Inst, Boston, MA, US;; 2 Carver Coll of Med, Univ of Iowa, Iowa City, US;; 3 Harvard Sch of Publ Hlth, Boston, MA, US;; and 4 Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US 10:30 134 Siglec-1 Is a Novel Dendritic Cell Receptor that Mediates HIV-1 Trans-infection Through Recognition of Viral Membrane Gangliosides Nuria Izquierdo-Useros* 1 , M Lorizate 2 , M Puertas 1 , M Rodriguez-Plata 1 , N Zangger 3 , M Pino 1 , I Erkizia 1 , A Telenti 3 , H-G Krausslich 2 , and J Martinez-Picado 1,4 1 AIDS Res Inst IrsiCaixa, Spain;; 2 Univ Heidelberg, Germany;; 3 Univ Hosp Ctr and Univ of Lausanne, Switzerland;; and 4 Inst Catalana de Recerca i Estudis Avancats, Spain 10:45 135 Inhibition of HIV-1 Vif Function by AML Factor CBF�-SMMHC Fusion Proteins Ke Zhao* 1 , J Du 1 , P Li 1 , Y Rui 1 , M Yan 1 , W Zhang 1 , X-F Yu 1,2 , and G Wang 1 1 Inst of Virology and AIDS Res, First Hosp of Jilin Univ, Changchun, China and 2 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US 11:00 136 Crystal Structure of HIV-1 Nef in Complex with the Hck SH3-SH2 Region Reveals New Intermolecular Interactions with Functional Implications John Jeff Alvarado*, S Tarafdar, T Smithgall, and J Yeh Univ of Pittsburgh, PA, US Program � 17 Wednesday March 6 Oral Sessions
- Page 1 and 2: Pocket Program CR I 2O13 20th Confe
- Page 3 and 4: vi General Information CROI 2013 AB
- Page 5 and 6: viii General Information CROI 2013
- Page 7 and 8: x Hotel Information CROI 2013 Map K
- Page 9 and 10: CROI 2013 Session 2 j Sunday, 9 am-
- Page 11 and 12: CROI 2013 Session 8 i Monday, 8:30-
- Page 13 and 14: CROI 2013 Session 12 k Monday, 10 a
- Page 15 and 16: CROI 2013 Session 16 b Monday, 1:30
- Page 17 and 18: CROI 2013 Session 20 e Monday, 4-6
- Page 19 and 20: CROI 2013 Session 26 11:00 85 Impac
- Page 21 and 22: CROI 2013 Session 31 1023 Risk Fact
- Page 23: CROI 2013 Session 34 e Tuesday, 4-6
- Page 27 and 28: CROI 2013 Session 45 11:00 153LB Om
- Page 29 and 30: CROI 2013 Session 49 1103 Attrition
- Page 31 and 32: CROI 2013 Session 52 e Wednesday, 4
- Page 33 and 34: CROI 2013 Session 57 188LB���
- Page 35 and 36: CROI 2013 Session 65 c Tuesday, 2:3
- Page 37 and 38: CROI 2013 Session 70 c Wednesday, 2
- Page 39 and 40: CROI 2013 Session 75 329 Impact of
- Page 41 and 42: CROI 2013 Session 82 369� ��
- Page 43 and 44: CROI 2013 Session 89 413 Risk of Cl
- Page 45 and 46: CROI 2013 Session 93 456 A Longitud
- Page 47 and 48: CROI 2013 Session 100 c Tuesday, 2:
- Page 49 and 50: CROI 2013 Session 106 c Monday, 2:3
- Page 51 and 52: CROI 2013 Session 111 c Wednesday,
- Page 53 and 54: CROI 2013 Session 117 616� ��
- Page 55 and 56: CROI 2013 Session 122 656 Compariso
- Page 57 and 58: CROI 2013 Session 125 c Tuesday, 2:
- Page 59 and 60: CROI 2013 Session 131 c Monday, 2:3
- Page 61 and 62: CROI 2013 Session 137 c Tuesday, 2:
- Page 63 and 64: CROI 2013 Session 144 809 Prevalenc
- Page 65 and 66: CROI 2013 Session 150 847 Improving
- Page 67 and 68: CROI 2013 Session 161 885 The Impac
- Page 69 and 70: CROI 2013 Session 171 + 924� �
- Page 71 and 72: CROI 2013 Session 180 c Wednesday,
- Page 73 and 74: CROI 2013 Session 187 994� ��
- Page 75 and 76:
CROI 2013 Session 192 1032b Changes
- Page 77 and 78:
CROI 2013 Session 197 1074� �
- Page 79 and 80:
CROI 2013 Session 199 nd 1113�
- Page 81 and 82:
POSTER SESSIONS Poster Hall open fr